by Mark Curtis | Mar 25, 2015
. Welcome to your Update from the Clinic for the month of February. Northwest Biotherapeutics received approval from Health Canada to proceed with its ongoing Phase 3 clinical study in Glioblastoma multiforme at clinical sites in Quebec. Sangamo and bluebird bio both...
by James Smith | Jan 26, 2015
With contributions from David Brindley . Cell-based treatments are being developed and marketed for a variety of indications: from rare orphan diseases like graft versus host disease (GvHD), to blockbuster conditions like diabetes and cardiovascular disease that...
by Stacey Johnson | Jan 23, 2015
. Signals’ mandate is to bring you, dear reader, blogs about stem cells, commercialization and biomaterials, but lately there hasn’t been much of the latter; therefore, I’ve decided to try to fill that gap. But before you get too excited, I am in no way an expert on...
Comments